Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched in oligodendrocyte progenitor cells (68 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8222
Sealed predictions
- NLGN2 in dopamine neurons, braak+0.11 (p 0.775) → -0.32 (p 0.407)receipt 8230
- NLGN2 in oligodendrocytes, braak-0.14 (p 0.714) → -0.62 (p 0.078)receipt 8229
Swarm cases
receipt 8230: NLGN2 in dopamine neurons, braak
- power
- full sample -0.13 (p 0.609, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.22 (p 0.389, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.228, n 18). could be the mix.
- skeptic
- leave-one-out range -0.26 to -0.02, sign flips 0; without severely affected donors -0.13 (p 0.609, n 18). fragile.
- cell type
- strongest in microglia: -0.73 (p 6.2e-4, n 18) vs -0.13 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NLGN2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NLGN2 · microglia · braak: substantia nigra, an independent cohort (already registered)
receipt 8229: NLGN2 in oligodendrocytes, braak
- power
- full sample -0.31 (p 0.204, n 18), 95% CI -0.68 to +0.18. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.182, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.33 (p 0.182, n 18). could be the mix.
- skeptic
- leave-one-out range -0.47 to -0.22, sign flips 0; without severely affected donors -0.31 (p 0.204, n 18). fragile.
- cell type
- strongest in microglia: -0.73 (p 6.2e-4, n 18) vs -0.31 in oligodendrocytes. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NLGN2 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NLGN2 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.43 p 0.131 (needs p < 2.6e-4)
Receipts
loading the receipts